Sağsöz, NevinOrbak, ZerrinNoyan, VolkanYücel, AykanUçar, BanuYıldız, Leyla2020-06-252020-06-252009closedAccess0015-02821556-5653https://doi.org/10.1016/j.fertnstert.2008.07.008https://hdl.handle.net/20.500.12587/4402Yucel, Aykan/0000-0002-5888-692XObjective: To evaluate short-term leptin and ghrelin concentrations in women with polycystic ovary syndrome (PCOS) who use low-dose oral contraceptives containing drospirenone. Design: Prospective study. Setting: Department of obstetrics and gynaecology in a university hospital. Patient(s): Twenty women with PCOS were enrolled in the study. Intervention(s): A low-dose oral contraceptive containing ethinyl estradiol and drospirenone was given for three cycles. Main Outcome Measure(s): Serum androstenedione, free T, T, dehydroepiandrosterone sulphate, sex hormone-binding globulin, FSH, LH, E-2, lipid profiles, leptin, and ghrelin levels were measured in each subject. Insulin resistance was estimated by the homeostasis model assessment-insulin resistance (HOMA-IR). Result(s): While leptin concentrations did not change with therapy, ghrelin levels increased statistically. Baseline leptin concentrations were correlated positively with body mass index, waist-to-hip ratio, insulin, and HOMA-IR and negatively with ghrelin. After controlling for body mass index and waist-to-hip ratio in a partial correlation analysis, leptin levels were not correlated with these parameters. Ghrelin was inversely correlated with body mass index, waist-to-hip ratio, insulin, HOMA-IR, and free T. Conclusion(s): In patients with PCOS, an oral contraceptive containing ethinyl estradiol and drospirenone increases ghrelin levels but not leptin levels in a 3-month period. Ghrelin might be related to the metabolic and androgenic changes in patients with PCOS. (Fertil Steril (R) 2009;92:660-6. (C)2009 by American Society for Reproductive Medicine.)eninfo:eu-repo/semantics/closedAccessPCOSleptinghrelindrospirenoneoral contraceptiveArticle92266066610.1016/j.fertnstert.2008.07.0082-s2.0-6765108535418973889Q1WOS:000268915200038Q1